Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2018 /
Results from RIALTO, blinatumomab for paediatric patients with B-cell precursor relapse / refractory ALL

1st - 4th Dec 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.12.18
Views: 644
Rating:

Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy

Dr Franco Locatelli speaks to ecancer at ASH 2018 about RIALTO study for paediatric patients with acute lymphoblastic leukaemia.

He describes the trial design, and some of the potential difficulties that had to be carefully monitored during the trial, including cytokine release syndrome.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation